RDA BioSharing WG + RDA Metabolomics IG OVERVIEWS

RDA BioSharing WG + RDA Metabolomics IG OVERVIEWS

• 1.
  The BioSharing Registry:connecting data policies, standards and databases in the life sciences The product of the WG will be a web-based, curated and searchable registry of content standards ensuring these are informative and discoverable, monitoring their development, evolution; their use in databases and adoption in data policies.
• 2.
  Goal: assist stakeholdersto make informed decisions Researchers, developers and curators lack support and guidance on how to best navigate and select content standards, understand their maturity, or find databases that implement them; Funders, journals and librarians do not have enough information to make informed decisions on which content standards or database to recommended in policies, or funded or implemented
• 3.
  Leveraging on anexisting effort: Current content: • Over 500 • Over 600 databases MoU with The International Conference on Systems Biology (ICSB), 22-28 August, 2008 Susanna-Assunta Sansone www.ebi.ac.uk/net-project 3 Current core functionalities: • search and filtering • submissions forms to add new records • “claim” functionality of existing records • person’s profile (as maintainer of records) associated to the ORCID profile • visualization and views of content Work to be done under in the RDA WG includes (but it is not limited to): • Develop assessment criteria for usability and popularity of standards • Assemble journal and funder policies re data storage • Associate standards to data policies and databases • Make fully cross-searchable • Continue to embed it in the ecosystem of complementary registries
• 4.
  Advisory Board andRDA Working Group core members – also early adopters Operational Team
• 5.
  The Metabolomics DataInteroperability IG: aims Christoph Steinbeck (chair), EMBL-EBI Shankar Subramanian (co-chair), University of California San Diego Susanna-Assunta Sansone (RDA community liaise), University of Oxford This IG aims to provide a forum to discuss all aspects of metabolomics data management and harmonization, focusing on barriers and potential solutions to those barriers, and exploration of and definition of data management policy In particular this IG will address: • interoperability of databases; • coordination of standards, e.g. convergence on shared terminology; • adaption of common tools and services, and workflows to enable data exchange, integration and publication. This IG will liaise with other existing technical and domain specific IGs and WGs under RDA, including (but not limited to) Big Data Analytics IG, Data Foundation and Terminology WG, Toxicogenomics IG, ELIXIR IG and will also bridge with external, existing world-wide activities
• 6.
  Initial memberships andlinks to existing efforts The initial membership of this IG is drawn from the leaders of several internationally recognized research and infrastructure programmes that are developing metabolomics databases and standards, such as the NIH Common Fund Metabolomics and ELIXIR, as well as from the International Metabolomics Society’s Board of Directors Masanori Arita, National Institute of Genetics, Japan Warwick Dunn, University of Birmingham, UK (Director of Metabolomics Society) Oliver Fiehn, UC Davis, USA (Director of Metabolomics Society) Roy Goodacre, University of Manchester, UK (Director of Metabolomics Society) Jules Griffin, MRC Human Nutrition Research, UK Ulrich Günther, University of Birmingham, UK Thomas Hankemeier, Leiden University, Netherlands Kenneth Haug, EMBL-EBI, UK Joachim Kopka, Max-Planck-Institute of Molecular Plant Physiology, Germany Steffen Neumann, Leibniz Institute of Plant Biochemistry Philippe Rocca-Serra, University of Oxford, UK Ute Roessner, University of Melbourne, Australia (Secretary of Metabolomics Society) Reza Salek, EMBL-EBI, UK Susanna-Assunta Sansone (RDA community liaise), University of Oxford Christoph Steinbeck (chair), EMBL-EBI Shankar Subramanian (co-chair), University of California San Diego Merlijn van Rijswijk, Dutch Techcentre for Life Sciences, Utrecht, Netherlands Mark Viant, University of Birmingham, UK (President of Metabolomics Society) Dirk Walther, Max-Planck-Institute of Molecular Plant Physiology, Germany David Wishart, University of Alberta, Canada